Shanghai Junshi Biosciences Co., Ltd. and AstraZeneca Pharmaceutical entered into a termination agreement in respect of the Original Agreement (the "Termination Agreement"), pursuant to which the Original Agreement was terminated with effect from 1 January 2022 (the "Termination Date") and the Company withdrew the promotion right of Toripalimab Injection as agreed in the Original Agreement. The commercialization team of the Company will be responsible for all promotion activities of Toripalimab Injection in mainland China. Termination of the promotion authorization: the authorization of the Company obtained by the Promoter under the Original Agreement shall be terminated and the Promoter shall no longer promote Toripalimab Injection.

If the Promoter entrusted any sub-licensee to carry out the promotion (whether in the name of the Company or in the name of the Promoter), the Promoter shall ensure that such sub-licensee has terminated the promotion activities in the name of the Company or the Promoter from the Termination Date. The parties shall actively communicate and negotiate to deal with the matters not addressed under the Original Agreement and the handover arrangement, and sign supplemental agreements for confirming the outstanding matters. On 28 February 2021, the Company entered into an exclusive promotion agreement (the "Original Agreement") with AstraZeneca Pharmaceutical Co., Ltd. ("AstraZeneca Pharmaceutical" or the "Promoter"), pursuant to which the Company granted AstraZeneca Pharmaceutical the exclusive promotion right of Toripalimab Injection (trade name: TUOYI®) for the urinary cancer indications to be approved subsequently for marketing in mainland China and the exclusive promotion right for all indications approved and to be approved in non-core urban areas.

The Company continues to be responsible for the promotion of other indications approved and to be approved excluding urinary cancer indications in core urban areas.